Results 1 to 10 of about 2,285,924 (374)

Transforming growth factor β1-mediated functional inhibition of mesenchymal stromal cells in myelodysplastic syndromes and acute myeloid leukemia

Haematologica, 2018
Mesenchymal stromal cells are involved in the pathogenesis of myelodysplastic syndromes and acute myeloid leukemia, but the underlying mechanisms are incompletely understood.
Stefanie Geyh, Manuel Rodríguez-Paredes, Paul Jäger, Annemarie Koch, Felix Bormann, Julian Gutekunst, Christoph Zilkens, Ulrich Germing, Guido Kobbe, Frank Lyko, Rainer Haas, Thomas Schroeder   +11 more
doaj   +2 more sources

TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes [PDF]

New England Journal of Medicine, 2016
et al,, Fronick, C. C., Fulton, R. S., Ley, T. J., Miller, C. A., O\u27Laughlin, M., Petti, A. A., Wartman, L. D., Wilson, R. K.   +8 more
core   +3 more sources

Clonal evolution in myelodysplastic syndromes

Nature Communications, 2017
Myelodysplastic syndromes are a broad group of haematopoietic malignancies that often progress to acute myeloid leukaemia. Here, the authors show that linear and branched evolution occurs within myelodysplastic syndrome and these patterns can be impacted
Pedro da Silva-Coelho, Leonie I. Kroeze, Kenichi Yoshida, Theresia N. Koorenhof-Scheele, Ruth Knops, Louis T. van de Locht, Aniek O. de Graaf, Marion Massop, Sarah Sandmann, Martin Dugas, Marian J. Stevens-Kroef, Jaroslav Cermak, Yuichi Shiraishi, Kenichi Chiba, Hiroko Tanaka, Satoru Miyano, Theo de Witte, Nicole M. A. Blijlevens, Petra Muus, Gerwin Huls, Bert A. van der Reijden, Seishi Ogawa, Joop H. Jansen   +22 more
doaj   +2 more sources

Myelodysplastic syndromes and autoimmune phenomena – case report and literature overview [PDF]

Liječnički vjesnik, 2023
Myelodysplastic syndromes are a heterogeneous group of hematopoiesis disorders, characterized by dysplastic changes in one or more hematopoietic lineages, ineffective hematopoiesis, and peripheral blood cytopenias.
Ana Zelić Kerep, Ana Kotris, Marino Narančić, Inga Mandac Smoljanović   +3 more
doaj   +1 more source

Myelodysplastic syndromes

Haematology, 2021
Myelodysplasia is one of the Cinderella subjects of paediatric haematology and oncology. Although cases are rare and probably do not account for more than 3% of haematological malignancies, patients presenting with these disorders pose a very serious ...
Rars Rars, Erythropoietic RCMD-RS
semanticscholar   +1 more source

Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes

Journal of Clinical Oncology, 2023
PURPOSE Myelodysplastic syndromes (MDS) are heterogeneous myeloid neoplasms in which a risk-adapted treatment strategy is needed. Recently, a new clinical-molecular prognostic model, the Molecular International Prognostic Scoring System (IPSS-M) was ...
E. Sauta, M. Robin, M. Bersanelli, E. Travaglino, M. Meggendorfer, Lin-Pierre Zhao, J. C. Caballero Berrocal, C. Sala, G. Maggioni, M. Bernardi, C. di Grazia, L. Vago, G. Rivoli, L. Borin, S. D'amico, C. Tentori, M. Ubezio, Alessia Campagna, Antonio Russo, D. Mannina, Luca Lanino, P. Chiusolo, L. Giaccone, M. Voso, M. Riva, E. Oliva, Matteo Zampini, E. Riva, O. Nibourel, Marilena Bicchieri, N. Bolli, A. Rambaldi, F. Passamonti, V. Savevski, A. Santoro, U. Germing, S. Kordasti, V. Santini, M. Díez-Campelo, G. Sanz, F. Solé, W. Kern, U. Platzbecker, L. Adès, P. Fenaux, T. Haferlach, G. Castellani, M. D. Della Porta   +47 more
semanticscholar   +1 more source

Myelodysplastic syndromes: 2023 update on diagnosis, risk‐stratification, and management

American journal of hematology/oncology, 2023
The myelodysplastic syndromes (MDS) are a very heterogeneous group of myeloid disorders characterized by peripheral blood cytopenias and increased risk of transformation to acute myelogenous leukemia (AML).
G. Garcia-Manero
semanticscholar   +1 more source

Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes

Journal of Clinical Oncology, 2021
PURPOSE Approximately 20% of patients with TP53-mutant myelodysplastic syndromes (MDS) achieve complete remission (CR) with hypomethylating agents. Eprenetapopt (APR-246) is a novel, first-in-class, small molecule that restores wild-type p53 functions in
D. Sallman, A. DeZern, G. Garcia-Manero, D. Steensma, G. Roboz, M. Sekeres, T. Cluzeau, K. Sweet, Amy F. McLemore, K. McGraw, J. Puskás, Ling Zhang, Jiqiang Yao, Qianxing Mo, L. Nardelli, N. Al Ali, E. Padron, G. Korbel, E. Attar, H. Kantarjian, J. Lancet, P. Fenaux, A. List, Alan F. Komrokji   +23 more
semanticscholar   +1 more source

Experiences and Support Needs of Caregivers of Patients with Higher-Risk Myelodysplastic Syndrome via Online Bulletin Board in the USA, Canada and UK

Oncology and Therapy, 2023
Introduction Patients with higher-risk myelodysplastic syndromes (MDS) face considerable challenges in disease management and often require caregiver support.
Pauline Frank, Anne Olshan, Tracey Iraca, Cindy Anthony, Sophie Wintrich, Emma Sasse   +5 more
doaj   +1 more source

Whole exome sequencing reveals a novel LRBA mutation and clonal hematopoiesis in a common variable immunodeficiency patient presented with hemophagocytic lymphohistiocytosis

Experimental Hematology & Oncology, 2021
Common variable immunodeficiency (CVID) was a kind of primary immunodeficiency disorders with heterogeneous phenotype and genotype. Lipopolysaccharide-responsive and beige-like anchor (LRBA) mutation was identified as disease associated in CVID, advanced
Yanling Ren, Feng Xiao, Fei Cheng, Xin Huang, Jianhu Li, Xiaogang Wang, Wei Lang, Xinping Zhou, Jianping Lan, Hongyan Tong   +9 more
doaj   +1 more source